The therapeutic community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s showing significant efficacy in clinical trials for addressing obesity. Unlike some available weight loss solutions, retatrutide appears to provide a more substantial reduction in body mass and improve metabolic health, particula